BCAB

BioAtla Inc

Apr 09 • 09:37AM ET

4.37

-0.07 -1.58 %

Healthcare • Biotechnology • USA • NASD

Apr 07, 12:01 PMReverse stock split implementation and financial distress drive 26% plunge in BCAB shares.

Peers: ADPT ALXO IDYA IMTX AGEN TCRX SRRK ANVS HOOK

| Held by: VTI VXF BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-50.76	Insider Own	18.94%	Shs Outstand	1.66M	Perf Week	-35.07%
Market Cap	7.24M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.34M	Perf Month	-49.22%
Enterprise Value	10.46M	PEG	-	EPS next Q	-	Inst Own	11.23%	Short Float	2.87%	Perf Quarter	-79.39%
Income	-59.61M	P/S	3.62	EPS this Y	-	Inst Trans	-0.21%	Short Ratio	0.75	Perf Half Y	-89.01%
Sales	2.00M	P/B	-	EPS next Y	-	ROA	-176.84%	Short Interest	0.04M	Perf YTD	-84.60%
Book/sh	-28.51	P/C	1.02	EPS next 5Y	-	ROE	-813.88%	52W High	71.50 -93.89%	Perf Year	-71.28%
Cash/sh	4.30	P/FCF	-	EPS past 3/5Y	28.18% 0.99%	ROIC	-	52W Low	3.92 11.48%	Perf 3Y	-97.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 36.06%	Gross Margin	81.35%	Volatility	19.55% 13.14%	Perf 5Y	-99.82%
Dividend TTM	-	EV/Sales	5.23	EPS Y/Y TTM	29.36%	Oper. Margin	-2965.25%	ATR (14)	1.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.37	Sales Y/Y TTM	-81.82%	Profit Margin	-2980.35%	RSI (14)	28.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.37	EPS Q/Q	45.09%	SMA20	-40.50%	Beta	1.10	Target Price	200.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-50.17%	Rel Volume	0.38	Prev Close	4.44
Employees	41	LT Debt/Eq	-	Earnings	Mar 31 AMC	SMA200	-81.91%	Avg Volume	51.42K	Price	4.37
IPO	Dec 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,298	Change	-1.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy	$4
Aug-13-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Nov-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-22	Initiated	JMP Securities	Mkt Outperform	$17
May-05-22	Downgrade	Credit Suisse	Outperform → Neutral	$35 → $5
Mar-21-22	Initiated	H.C. Wainwright	Buy	$25
Oct-15-21	Resumed	BTIG Research	Buy	$68
Jun-28-21	Initiated	ROTH Capital	Buy	$75
May-05-21	Resumed	Credit Suisse	Outperform	$68
Apr-26-21	Resumed	Credit Suisse	Outperform	$68
Jan-11-21	Initiated	JP Morgan	Overweight	$45
Jan-11-21	Initiated	Jefferies	Buy	$51
Jan-11-21	Initiated	Credit Suisse	Outperform	$49
Jan-11-21	Initiated	BTIG Research	Buy	$47

Show Previous Ratings

Mar-31-26 04:06PM	BioAtla Announces Share Consolidation (GlobeNewswire) -16.40%
04:05PM	BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
Mar-02-26 07:30AM	BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets (GlobeNewswire) -17.54%
Dec-31-25 07:00AM	BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) (GlobeNewswire) -20.82%
Nov-21-25 12:25AM	BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing (GlobeNewswire) -25.07%
12:04AM	Loading…
Nov-14-25 12:04AM	BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... (GuruFocus.com) +19.75%
Nov-13-25 04:05PM	BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire)
Nov-07-25 09:00AM	BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas (GlobeNewswire) +7.23%
Nov-05-25 08:00AM	BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 (GlobeNewswire)
Oct-23-25 08:00AM	BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society (GlobeNewswire) +9.39%
Oct-20-25 08:00AM	BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 (GlobeNewswire) -26.00%
Oct-03-25 09:00AM	BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 (GlobeNewswire)
Sep-08-25 08:00AM	BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA (GlobeNewswire) +13.92%
Aug-07-25 04:05PM	BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire) -7.16%
Aug-04-25 08:00AM	BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 (GlobeNewswire)
08:00AM	Loading…
Jul-17-25 08:00AM	BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting (GlobeNewswire)
Jul-03-25 08:00AM	BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress (GlobeNewswire) -5.43%
Jun-02-25 08:00AM	BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen (GlobeNewswire) +24.69%
May-07-25 03:21AM	BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... (GuruFocus.com) -5.74%
May-06-25 04:05PM	BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire) -8.19%
Apr-30-25 08:00AM	BioAtla to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
Apr-29-25 08:00AM	BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025 (GlobeNewswire) +11.35%
Apr-24-25 08:00AM	BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +19.86%
Apr-23-25 10:05AM	BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +10.03%
Mar-28-25 12:45PM	Q4 2024 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
03:04AM	BioAtla Inc (BCAB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Mar-27-25 06:18PM	BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-20-25 08:00AM	BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings (GlobeNewswire)
Mar-19-25 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 (GlobeNewswire)
12:00PM	Loading…
Jan-02-25 12:00PM	BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-20-24 09:00AM	BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points (GlobeNewswire) -41.82%
Dec-16-24 08:00AM	BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting (GlobeNewswire) -6.90%
Dec-10-24 08:00AM	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic and Translational Science Meeting (GlobeNewswire)
08:00AM	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting (GlobeNewswire)
Nov-08-24 04:03PM	BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -5.41% +12.86%
Nov-07-24 04:01PM	BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire) +7.77%
Oct-31-24 08:00AM	BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 (GlobeNewswire)
Oct-20-24 04:06PM	BioAtla, Inc. (BCAB): Among Michael Burry's Top 10 Stock Picks Heading Into 2025 (Insider Monkey)
Oct-09-24 05:57PM	BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
Oct-04-24 09:05AM	BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -6.38%
Oct-01-24 08:00AM	BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress (GlobeNewswire)
Sep-23-24 07:30AM	BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody (GlobeNewswire)
Sep-16-24 08:00AM	BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting (GlobeNewswire) -7.18%
Sep-09-24 08:00AM	BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting (GlobeNewswire)
Aug-28-24 08:00AM	BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-08-24 04:05PM	Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire) +5.76%
Aug-01-24 08:00AM	BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024 (GlobeNewswire)
Jul-31-24 01:11PM	These 2 Strong Buy Penny Stocks Are Poised for a Big Rally, Say Analysts (TipRanks) +11.04%
Jul-25-24 05:39PM	BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day (GlobeNewswire)
Jul-24-24 12:54PM	BioAtla receives FDA fast track designation for ozuriftamab vedotin (Pharmaceutical Technology)
Jul-23-24 08:00AM	BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (GlobeNewswire)
Jun-27-24 08:00AM	BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 (GlobeNewswire)
May-29-24 08:00AM	BioAtla to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -9.52%
May-23-24 05:05PM	BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.89% -18.57%
May-15-24 08:18AM	BioAtla, Inc. (NASDAQ:BCAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +14.94%
07:01AM	BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ... (GuruFocus.com)
May-14-24 08:57PM	BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire)
May-08-24 08:00AM	BioAtla to Participate in the Citizens JMP Life Sciences Conference (GlobeNewswire)
May-07-24 08:00AM	BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 (GlobeNewswire)
May-06-24 09:14AM	BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance (MT Newswires)
08:00AM	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors (GlobeNewswire)
Apr-24-24 04:35PM	BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-27-24 10:07AM	BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.95%
07:56AM	Q4 2023 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-26-24 09:54PM	BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023 (InvestorPlace) +29.18%
05:33PM	BioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-19-24 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024 (GlobeNewswire) +5.13%
Mar-07-24 08:00AM	BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Dec-20-23 08:00AM	BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 08:00AM	BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types (GlobeNewswire) +23.26%
Dec-06-23 08:00AM	BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023 (GlobeNewswire)
Dec-05-23 08:00AM	BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event (GlobeNewswire)
Nov-30-23 08:00AM	BioAtla to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:00AM	BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC (GlobeNewswire) +8.16%
Nov-12-23 09:24AM	BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:01PM	BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) -6.25%
Nov-06-23 04:05PM	BioAtla to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-12-23 07:30AM	BioAtla's Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award (GlobeNewswire) -5.46%
Oct-10-23 07:30AM	BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023 (GlobeNewswire) +15.12%
Sep-06-23 08:00AM	BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:01PM	BioAtla to Participate in Upcoming Investor Conferences in August (GlobeNewswire) -8.67%
06:48AM	BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-02-23 11:31AM	Q2 2023 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-23 04:01PM	BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Jul-25-23 08:00AM	BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023 (GlobeNewswire)
Jul-07-23 07:09AM	With 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional owners (Simply Wall St.)
Jun-26-23 08:00AM	BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index (GlobeNewswire) -9.43%
May-31-23 08:00AM	BioAtla to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +14.33%
May-08-23 04:05PM	BioAtla to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire) -9.44%
May-04-23 08:00AM	BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 (GlobeNewswire)
Apr-29-23 09:29AM	We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research) +8.94%
Mar-27-23 07:12AM	BioAtla, Inc. (NASDAQ:BCAB) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.51%
Mar-24-23 11:31AM	Q4 2022 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-23-23 04:05PM	BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-16-23 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights (GlobeNewswire)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAB

BioAtla Inc

Upgrade your Finviz experience